Molecule Information
General Information of the Molecule (ID: Mol00940)
| Name |
DNA-directed RNA polymerase subunit beta (RPOB)
,Mycobacterium tuberculosis
|
||||
|---|---|---|---|---|---|
| Synonyms |
RNAP subunit beta; RNA polymerase subunit beta; Transcriptase subunit beta; Rv0667; MTCI376.08c
Click to Show/Hide
|
||||
| Molecule Type |
Protein
|
||||
| Gene Name |
rpoB
|
||||
| Gene ID | |||||
| Sequence |
MLEGCILADSRQSKTAASPSPSRPQSSSNNSVPGAPNRVSFAKLREPLEVPGLLDVQTDS
FEWLIGSPRWRESAAERGDVNPVGGLEEVLYELSPIEDFSGSMSLSFSDPRFDDVKAPVD ECKDKDMTYAAPLFVTAEFINNNTGEIKSQTVFMGDFPMMTEKGTFIINGTERVVVSQLV RSPGVYFDETIDKSTDKTLHSVKVIPSRGAWLEFDVDKRDTVGVRIDRKRRQPVTVLLKA LGWTSEQIVERFGFSEIMRSTLEKDNTVGTDEALLDIYRKLRPGEPPTKESAQTLLENLF FKEKRYDLARVGRYKVNKKLGLHVGEPITSSTLTEEDVVATIEYLVRLHEGQTTMTVPGG VEVPVETDDIDHFGNRRLRTVGELIQNQIRVGMSRMERVVRERMTTQDVEAITPQTLINI RPVVAAIKEFFGTSQLSQFMDQNNPLSGLTHKRRLSALGPGGLSRERAGLEVRDVHPSHY GRMCPIETPEGPNIGLIGSLSVYARVNPFGFIETPYRKVVDGVVSDEIVYLTADEEDRHV VAQANSPIDADGRFVEPRVLVRRKAGEVEYVPSSEVDYMDVSPRQMVSVATAMIPFLEHD DANRALMGANMQRQAVPLVRSEAPLVGTGMELRAAIDAGDVVVAEESGVIEEVSADYITV MHDNGTRRTYRMRKFARSNHGTCANQCPIVDAGDRVEAGQVIADGPCTDDGEMALGKNLL VAIMPWEGHNYEDAIILSNRLVEEDVLTSIHIEEHEIDARDTKLGAEEITRDIPNISDEV LADLDERGIVRIGAEVRDGDILVGKVTPKGETELTPEERLLRAIFGEKAREVRDTSLKVP HGESGKVIGIRVFSREDEDELPAGVNELVRVYVAQKRKISDGDKLAGRHGNKGVIGKILP VEDMPFLADGTPVDIILNTHGVPRRMNIGQILETHLGWCAHSGWKVDAAKGVPDWAARLP DELLEAQPNAIVSTPVFDGAQEAELQGLLSCTLPNRDGDVLVDADGKAMLFDGRSGEPFP YPVTVGYMYIMKLHHLVDDKIHARSTGPYSMITQQPLGGKAQFGGQRFGEMECWAMQAYG AAYTLQELLTIKSDDTVGRVKVYEAIVKGENIPEPGIPESFKVLLKELQSLCLNVEVLSS DGAAIELREGEDEDLERAAANLGINLSRNESASVEDLA Click to Show/Hide
|
||||
| 3D-structure |
|
||||
| Function |
DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.
Click to Show/Hide
|
||||
| Uniprot ID | |||||
| Click to Show/Hide the Complete Species Lineage | |||||
Type(s) of Resistant Mechanism of This Molecule
Drug Resistance Data Categorized by Drug
Approved Drug(s)
2 drug(s) in total
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Disease Class: Tuberculosis [ICD-11: 1B10.0] | [1] | |||
| Resistant Disease | Tuberculosis [ICD-11: 1B10.0] | |||
| Resistant Drug | Isoniazid | |||
| Molecule Alteration | Mutation | . |
||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Mycobacterium tuberculosis H37Rv | 83332 | ||
| Mycobacterium tuberculosis isolates | 1773 | |||
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Mechanism Description | Monoresistance to rifampicin and isoniazid was found in 11% (95% CI: 0.077-0.150; p, 0.087) and 8.5% (95% CI: 0.056-0.123; p, 0.692) of all the patients, respectively. Resistance to RIF and INH among newly diagnosed patients was 10.2% and 8.6%, while among previously treated patients, resistance to RIF and INH was 23.5% and 5.9% respectively. Furthermore, 4.9% of the samples from newly diagnosed with INH monoresistance, were found to have mutations in the InhA region while 8.6% had mutations in the katG region, a condition that can lead to phenotypic isoniazid drug resistance. | |||
| Disease Class: Urinary tuberculosis [ICD-11: 1G80.0] | [2] | |||
| Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
| Resistant Drug | Isoniazid | |||
| Molecule Alteration | Missense mutation | p.S531L |
||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
| Experiment for Molecule Alteration |
Gene sequencing assay | |||
| Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
| Disease Class: Urinary tuberculosis [ICD-11: 1G80.0] | [2] | |||
| Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
| Resistant Drug | Isoniazid | |||
| Molecule Alteration | Missense mutation | p.S315T1 |
||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
| Experiment for Molecule Alteration |
Gene sequencing assay | |||
| Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Disease Class: Tuberculosis [ICD-11: 1B10.0] | [1] | |||
| Resistant Disease | Tuberculosis [ICD-11: 1B10.0] | |||
| Resistant Drug | Rifampin | |||
| Molecule Alteration | Mutation | . |
||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Mycobacterium tuberculosis H37Rv | 83332 | ||
| Mycobacterium tuberculosis isolates | 1773 | |||
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Mechanism Description | Monoresistance to rifampicin and isoniazid was found in 11% (95% CI: 0.077-0.150; p, 0.087) and 8.5% (95% CI: 0.056-0.123; p, 0.692) of all the patients, respectively. Resistance to RIF and INH among newly diagnosed patients was 10.2% and 8.6%, while among previously treated patients, resistance to RIF and INH was 23.5% and 5.9% respectively. Furthermore, 4.9% of the samples from newly diagnosed with INH monoresistance, were found to have mutations in the InhA region while 8.6% had mutations in the katG region, a condition that can lead to phenotypic isoniazid drug resistance. | |||
| Disease Class: Urinary tuberculosis [ICD-11: 1G80.0] | [2] | |||
| Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
| Resistant Drug | Rifampin | |||
| Molecule Alteration | Missense mutation | p.S531L |
||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
| Experiment for Molecule Alteration |
Gene sequencing assay | |||
| Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
| Disease Class: Urinary tuberculosis [ICD-11: 1G80.0] | [2] | |||
| Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
| Resistant Drug | Rifampin | |||
| Molecule Alteration | Missense mutation | p.S315T1 |
||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
| Experiment for Molecule Alteration |
Gene sequencing assay | |||
| Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Yu.
